{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:36:50Z","timestamp":1790635010202,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102869","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:30:55Z","timestamp":1781915455000},"page":"102869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeted inhibition of ATR kinase promotes antitumor immunity in HNSCC through enhanced STING activation and T cell function"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-4051","authenticated-orcid":false,"given":"Fabio HB","family":"da Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsuki","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2486-7317","authenticated-orcid":false,"given":"Tsung-You","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7062-466X","authenticated-orcid":false,"given":"Kento","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason D.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratna","family":"Veeramachaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9088-7957","authenticated-orcid":false,"given":"Roberto","family":"Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad C.","family":"Sandulache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6320-6255","authenticated-orcid":false,"given":"Jeffrey N.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102869_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tranon.2026.102869_bib0002","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.tranon.2026.102869_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102869_bib0004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/medsci11020042","article-title":"Epidemiology, Risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med. Sci. (Basel)"},{"key":"10.1016\/j.tranon.2026.102869_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jama.2025.21733","article-title":"Head and Neck cancer A review","volume":"335","author":"Dunn","year":"2026","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.tranon.2026.102869_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040):a randomized, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102869_bib0007","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102869_bib0008","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102869_bib0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and Adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102869_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1031944","article-title":"Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma","volume":"12","author":"Lei","year":"2022","journal-title":"Front. Oncol."},{"issue":"35","key":"10.1016\/j.tranon.2026.102869_bib0011","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2014.06.003","article-title":"DNA damage and innate immunity: links and trade-offs","volume":"35","author":"Chatzinikolaou","year":"2014","journal-title":"Trends. Immunol."},{"issue":"20","key":"10.1016\/j.tranon.2026.102869_bib0012","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.3390\/ijms21207504","article-title":"DNA damage response and immune defense","volume":"21","author":"Nastasi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.tranon.2026.102869_bib0013","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mc.23384","article-title":"Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma","volume":"61","author":"Karukonda","year":"2022","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.tranon.2026.102869_bib0014","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-042320-025136","article-title":"A tale of two checkpoints: ATR inhibition and PD-(L)1 blockade","volume":"73","author":"Ngo","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.tranon.2026.102869_bib0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102869_bib0016","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) Kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tranon.2026.102869_bib0017","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102869_bib0018","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtho.2022.07.074","article-title":"OA15.05\u2014HUDSON: an open-label, multi-drug, biomarker-directed phase 2 study in NSCLC patients who progressed on anti-PD-(L)1 therapy","volume":"17","author":"Besse","year":"2022","journal-title":"J. Thoracic. Oncol."},{"key":"10.1016\/j.tranon.2026.102869_bib0019","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0194599812442037","article-title":"Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer","volume":"147","author":"Judd","year":"2012","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"757","key":"10.1016\/j.tranon.2026.102869_bib0020","article-title":"Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma","volume":"5","author":"Shi","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.tranon.2026.102869_bib0021","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1535-7163.MCT-14-0735-T","article-title":"Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence","volume":"14","author":"Osman","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2026.102869_bib0022","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat. Commun."},{"issue":"39","key":"10.1016\/j.tranon.2026.102869_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado4618","article-title":"ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer","volume":"10","author":"Taniguchi","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tranon.2026.102869_bib0024","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment","volume":"36","author":"Woo","year":"2015","journal-title":"Trends. Immunol."},{"key":"10.1016\/j.tranon.2026.102869_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102869_bib0026","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1165\/rcmb.2015-0012OC","article-title":"Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages","volume":"53","author":"Tarique","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102869_bib0027","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s13402-023-00817-6","article-title":"Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells","volume":"46","author":"Li","year":"2023","journal-title":"Cell Oncol. (Dordr)"},{"issue":"3","key":"10.1016\/j.tranon.2026.102869_bib0028","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/1541-7786.MCR-21-0366","article-title":"Chk1 Inhibition potently blocks STAT3 Tyrosine705 phosphorylation, DNA-binding activity, and activation of downstream targets in Human multiple myeloma cells","volume":"20","author":"Zhou","year":"2022","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.102869_bib0029","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1172\/JCI60083","article-title":"E, STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients","volume":"123","author":"Vasquez-Dunddel","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2026.102869_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175336","article-title":"Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation","volume":"12","author":"Awad","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.tranon.2026.102869_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer","volume":"109","author":"Parkes","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2026.102869_bib0032","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.tranon.2026.102869_bib0033","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102869_bib0034","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2044103","article-title":"IFN-\u03b3 activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation","volume":"11","author":"Xiong","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tranon.2026.102869_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106012","article-title":"The mouse oral carcinoma (MOC) model: a 10-year retrospective on model development and head and neck cancer investigations","volume":"132","author":"Kono","year":"2022","journal-title":"Oral Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:30:03Z","timestamp":1787225403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S1936523326002068"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102869","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted inhibition of ATR kinase promotes antitumor immunity in HNSCC through enhanced STING activation and T cell function","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102869"}}